AP NEWS
This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Globe Newswire
This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation.

CLASS ACTION UPDATE for IMMU, DBVT, DXC and ALKS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

February 22, 2019

NEW YORK, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.

Immunomedics, Inc. (NASDAQ: IMMU) Class Period: February 8, 2018 - January 18, 2019 Lead Plaintiff Deadline: February 25, 2019 Join the action: https://www.zlk.com/pslra-1/immunomedics-inc-loss-form?wire=3

The lawsuit alleges: Immunomedics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Immunomedics’ Morris Plains, New Jersey drug substance manufacturing facility was not in compliance with FDA requirements; (ii) the Company’s Quality Control Unit did not possess the authority to investigate and correct critical FDA violations occurring at the Morris Plains, New Jersey facility; (iii) the Company suffered a February 2018 data integrity breach at the Morris Plains, New Jersey facility which, among other issues, included the backdating records and manipulation of bioburden samples; (iv) the Company’s Chemistry, Manufacturing and Control data submitted in connection with its BLA for sacituzumab govitecan was insufficient to support FDA approval; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times

To learn more about the Immunomedics, Inc. class action contact jlevi@levikorsinsky.com.

DBV Technologies S.A. (NASDAQ: DBVT) Class Period: February 14, 2018 - December 19, 2018 Lead Plaintiff Deadline: March 18, 2019 Join the action: https://www.zlk.com/pslra-1/dbv-technologies-s-a-loss-form?wire=3

The lawsuit alleges: DBV Technologies S.A. made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (1) DBV Technologies’ Biologics License Application (“BLA”) for Viaskin Peanut failed to provide the FDA with sufficient data on manufacturing procedures and quality controls; (2) consequently, DBV Technologies voluntarily withdrew the BLA for Viaskin Peanut; and (3) as a result, defendants’ statements about DBV Technologies’ business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.

To learn more about the DBV Technologies S.A. class action contact jlevi@levikorsinsky.com.

DXC Technology Company (NYSE: DXC) Class Period: February 8, 2018 - November 6, 2018 Lead Plaintiff Deadline: February 25, 2019 Join the action: https://www.zlk.com/pslra-1/dxc-technology-company-loss-form?wire=3

The lawsuit alleges: DXC Technology Company made materially false and/or misleading statements and/or failed to disclose that: (a) the Company had changed or planned to change the operations of its sales teams, deploying generalized sales teams as opposed to the specialized teams that were better capable of delivering specialized services to its clients; (b) the Company’s workforce optimization strategy of sharply reducing staff while reducing costs was resulting in a shortage of sales personnel who could execute on demand for services, thereby risking and ultimately losing sales and revenue opportunities; (c) in light of the above, the Company’s revenue and financial performance guidance for the fiscal year 2019 and its reaffirmation of the guidance during the Class Period was without a reasonable basis.

To learn more about the DXC Technology Company class action contact jlevi@levikorsinsky.com.

Alkermes plc (NASDAQGS: ALKS) Class Period: February 17, 2017 - November 1, 2018 Lead Plaintiff Deadline: February 25, 2019 Join the action: https://www.zlk.com/pslra-1/alkermes-plc-loss-form?wire=3

The lawsuit alleges that, during the class period, Alkermes plc made materially false and/or misleading statements and/or failed to disclose that: (1) the FDA had advised Alkermes to follow a certain protocol in connection with its New Drug Application submission for its drug ALKS 5461; (2) Alkermes had failed to follow that protocol; (3) consequently, an FDA advisory committee voted 21 to 2 against the approval of ALKS 5461; and (4) as a result, Alkermes’ public statements were materially false and/or misleading at all relevant times.

To learn more about the Alkermes plc class action contact jlevi@levikorsinsky.com.

You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Levi & Korsinsky, LLPJoseph E. Levi, Esq.55 Broadway, 10th FloorNew York, NY 10006 jlevi@levikorsinsky.com Tel: (212) 363-7500Toll Free: (877) 363-5972Fax: (212) 363-7171 www.zlk.com